Lipe & Dalton Sells 200 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Lipe & Dalton cut its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 1.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,155 shares of the company’s stock after selling 200 shares during the period. Lipe & Dalton’s holdings in GE HealthCare Technologies were worth $872,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. LGT Financial Advisors LLC lifted its stake in shares of GE HealthCare Technologies by 1,673.3% in the 3rd quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in GE HealthCare Technologies in the 3rd quarter worth approximately $26,000. Capital Performance Advisors LLP bought a new stake in GE HealthCare Technologies in the third quarter valued at approximately $26,000. Darwin Wealth Management LLC bought a new stake in GE HealthCare Technologies in the third quarter valued at approximately $31,000. Finally, Continuum Advisory LLC boosted its stake in shares of GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after purchasing an additional 168 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

GE HealthCare Technologies Stock Down 1.1 %

Shares of NASDAQ:GEHC opened at $91.09 on Friday. The firm has a market capitalization of $41.66 billion, a P/E ratio of 21.04, a P/E/G ratio of 3.20 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. The stock has a 50 day moving average price of $85.05 and a 200-day moving average price of $85.83. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. The business had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. As a group, equities research analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

Analysts Set New Price Targets

GEHC has been the topic of several analyst reports. Citigroup lifted their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Wells Fargo & Company boosted their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their target price for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $97.67.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.